Austin Russian: How Fragmentation Delays Rare Disease Therapy Access

In the first part of his interview with Pharmaceutical Commerce, live from Asembia AXS26 in Las Vegas, Austin Russian, SVP of Program Excellence at PANTHERx Rare, focuses on the operational factors that can delay patient access to rare disease therapies. As more orphan drugs enter the market, stakeholders are paying closer attention to how access is managed across an increasingly complex care journey.

Russian points to fragmentation as a key challenge. Patients often interact with multiple parties, including prescribers, insurers, pharmacies, and manufacturers, without a single entity coordinating the process. He notes that this can lead to miscommunication and delays, particularly when combined with the variability and limited data that characterize many rare diseases.

The discussion also explores how the orphan drug launch landscape is being approached. Russian describes launch not as a single event tied to an approval date, but as a longer process that continues as therapies are introduced into real-world use. As that happens, stakeholders gather new insights and adjust their approach to better support patient access.

Overall, the conversation centers on how coordination, communication, and adaptability play a role in improving the path from approval to patient access in the rare disease space.